Modulation of the Late Sodium Current by ATX-II and Ranolazine Affects the Reverse Use-Dependence and Proarrhythmic Liability of IKrblockade
Shaobin Jia,Jiangfan Lian,Donglin Guo,Xiaolin Xue,Chinmay Patel,Lin Yang,Zuyi Yuan,Aiqun Ma,Gan-Xin Yan
DOI: https://doi.org/10.1111/j.1476-5381.2010.01181.x
IF: 7.3
2010-01-01
British Journal of Pharmacology
Abstract:BACKGROUND AND PURPOSEDrug-induced torsades de pointes (TdP) often occurs during bradycardia due to reverse use-dependence. We tested the hypothesis that inhibition or enhancement of late sodium current (I-Na,I-L) could modulate the drug-induced reverse use-dependence in QT and Tp-e (an index of dispersion of repolarization), and therefore the liability for TdP.EXPERIMENTAL APPROACHArterially perfused rabbit left ventricular wedge preparations were used. Action potentials from the endocardium were recorded simultaneously with a transmural ECG. The effects of Anemonia sulcata toxin (ATX-II) (an I-Na,I-L enhancer), d,l-sotalol, clarithromycin and ranolazine (an I-Na,I-L blocker) on rate-dependent changes in QT, Tp-e and proarrhythmic events were tested, either alone or in combination. Rate-dependent QT and Tp-e slopes and TdP score (a combined index of TdP liability) were calculated at control and during drug infusion.KEY RESULTSATX-II (30 nM) and sotalol (300 mu M) caused a marked increase in QT and Tp-e intervals, steeper QT-basic cycle length (BCL) and Tp-e-BCL slopes (i.e. reverse use-dependence), and TdP. Addition of ranolazine (15 mu M) to ATX-II or sotalol significantly attenuated QT-BCL, Tp-e-BCL slopes and the increased TdP scores. In contrast, clarithromycin (100 mu M) moderately prolonged QT and Tp-e without causing R-on-T extrasystole or TdP, but addition of ATX-II (1 nM) to clarithromycin markedly amplified the QT-BCL and Tp-e-BCL slopes and further increased TdP score.CONCLUSION AND IMPLICATIONSModulation of I-Na,I-L altered drug-induced reverse use-dependence related to QT as well as Tp-e, indicating that inhibition of I-Na,I-L can markedly reduce the TdP liability of agents that prolong QT intervals.